Table 2.
Cell viabilities from MTT assay in combined treatments compared to H1N1
| Compound | Cell viability (mean ± SD) | ||
|---|---|---|---|
| Co-pen | Pre-pen | Post-pen | |
| Ascorbate + H1N1 | 2.97 ± 0.01** | 1.82 ± 0.79** | 3.69 ± 0.21** |
| Acetate + H1N1 | 1.11 ± 0.02** | 1.08 ± 0.02** | 0.82 ± 0.09** |
| Citrate + H1N1 | 1.34 ± 0.41** | 1.03 ± 0.04** | 0.92 ± 0.03** |
| Amantadine hydrochloride + H1N1 | 0.89 ± 0.03** | 0.52 ± 0.04* | 0.54 ± 0.05* |
| Oseltamivir carboxylate + H1N1 | 0.98 ± 0.00** | 0.93 ± 0.00** | 0.92 ± 0.03** |
| H1N1 | 0.23 ± 0.04 | 0.23 ± 0.04 | 0.23 ± 0.04 |
Data presented as mean ± SD are averages of 4 independent MTT assays
*Significantly and** highly significantly different from untreated sample (P ≤ 0.05 and P ≤ 0.01) were analyzed by SPSS, Tukey post-hoc test